We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 108.24 | 109.30 | 109.37 | 0 | 01:00:00 |
Juno Therapeutics Inc. said a clinical hold was placed on its trial of a potential leukemia treatment after two patient deaths last week.
Juno shares fell 30% to $28.46 in after-hours trading Thursday.
The Phase 2 trial of JCAR015 tested the drug in patients with relapsed or refractory B cell acute lymphoblastic leukemia. As of 2015, the biopharmaceutical company said JCAR015 was its most advanced product candidate. In June, the company reported favorable JCAR015 results from a Phase 1 study.
The deaths occurred after the addition of fludarabine to the pre-conditioning regimen. Juno has proposed to the U.S. Food and Administration to continue the trial with cyclophosphamide pre-conditioning alone.
Juno will submit a response to the FDA this week that includes revisions to the trial protocol and patient consent forms.
The company said its plans for other CD19-directed CAR-T cell product candidates, including JCAR017, aren't affected.
Seattle-based Juno launched in 2013 with discoveries by scientists at Fred Hutchinson Cancer Research, Memorial Sloan Kettering Cancer Center and the Seattle Children's Research Institute.
Last year, Juno announced a 10-year collaboration with Celgene Corp. focused on treatments for cancer and autoimmune diseases. Celgene invested about $1 billion in Juno initially, including an $849.8 million stock purchase and a $150 million payment.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
July 07, 2016 17:15 ET (21:15 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions